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The aim of the current study was to formulate and optimize the formulation on the basis of in vitro performance of microsphere.
A3 2 full factorial design was employed to study the eﬀect of independent variables, polymer-to-drug ratio (X1) and stirring speed
(X2), on dependent variables, encapsulation eﬃciency, particle size, and time to 80% drug release. The best batch exhibited a high
entrapment eﬃciency of 70% and mean particle size 290µm. The drug release was also sustained for more than 12 hours. The
study helped in ﬁnding the optimum formulation with excellent sustained drug release.
1.Introduction
Microencapsulation is a useful method for prolonging drug
release from dosage form and reducing adverse eﬀect [1].
Recently, dosage forms that can precisely control the release
rates and target drugs speciﬁc body site have made an
enormous impact in the formulation and development of
n o v e ld r u gd e l i v e rys y s t e m .M i c r o s p h e r e sf o r ma ni m p o rt a n t
part of such novel drug delivery system [2–4]. Microspheres
are one of the multiparticulate delivery systems and are
prepared to obtain prolonged or controlled drug delivery, to
improve bioavailability or stability and to target drug to
speciﬁc sites. Microspheres can also oﬀer advantages like
limiting ﬂuctuation within therapeutic range, reducing side
eﬀects, decreasing dosing frequency, and improving patient
compliance [5, 6].
Ethylcellulose (EC) that is a hydrophobic and pH-
independent polymer has been widely used in the prepared
sustained release dosage forms of a water-soluble material
[7–10]. The substance encapsulated in the microsphere is
released under the inﬂuence of a speciﬁc stimulus at a spec-
iﬁed stage [11]. Whereas interaction between dissolution
media, polymer, and drug is the primary factors in release
control [12, 13], various formulation variables inﬂuence
drug release rate to greater or lesser extent. Thus, drug
loading [14, 15], drug/polymer ratio [16–18], and drug
particle size [19] have been shown to aﬀect drug release from
EC matrices.
Stavudine is a nucleotide reverse transcriptase inhibitors
and primarily used in the treatment of one of the most
common chronic disease of the planet, AIDS. It has short
biological half-life 0.8–1.5h, and low daily dose of 30mg
is required [20, 21].The frequency of dosing is more. To
overcome this problem it is necessary to desire sustained
release dosage forms to improve patient compliance.
Responsesurfacemethodology(RSM)iswidelypracticed
approachinthedevelopmentandoptimizationofdrugdeliv-
ery devices. Based on the principle of design of experiments
(DoEs), the methodology encompasses the use of various
types of experimental designs, generation of polynomial
equations, and mapping of the response over the experimen-
tal domain to determine the optimum formulation(s) [22–
27]. The technique requires minimum experimentation and
t i m e ,t h u sp r o v i n gt ob ef a rm o r ee ﬀective and cost-eﬀective
than the conventional methods of formulating dosage forms.
The current study aims at developing and optimizing
microspheres of stavudine using RSM, as it may prove to be
more productive than the conventional systems by virtue of
prolongation of drug residence time in gastrointestinal tract.
Further, microsphere of the drug would involve relatively2 ISRN Pharmaceutics
more economical and less complicated technology vis-` a-vis
many other drug delivery devices. Computer-aided optimi-
zation technique, using a full factorial design, was employed
to investigate the eﬀect of 2 independent variables (factors)
(i.e., the drug-to-polymer ratio and stirring speed) on parti-
cle size, encapsulation eﬃciency, and drug release.
2.MaterialsandMethods
2.1. Materials. Stavudine was obtained from Cipla Ltd,
Mumbai, India as gift sample. EC was procured from CDH
(P) Ltd, New Delhi, India. Acetone and light liquid paraﬃn
were obtained from Ranbaxy Fine Chemical Ltd., New Delhi,
India used as dispersion media. n-Hexane (Ranbaxy Fine
Chemical Ltd., New Delhi, India) was a washing agent. All
c h e m i c a l sr e c e i v e dw e r eo fa n a l y t i c a lg r a d ea n dw e r eu s e da s
such.
2.2. Methods. Microspheres of ethylcellulose were prepared
by emulsion solvent diﬀusion technique, using EC as a
polymeric retardant material. Polymer was dissolved in
5mL organic solvent consisting of acetonitrile and dichlo-
romethane (1:1 ratio). The resultant solution was extruded
throughasyringe(G20)intothesolutionofdruginaqueous
medium (2mL) under stirring at 500rpm using mechanical
stirrer (Remi Motors, India) for 5 minutes, to form primary
emulsion(w/o).Thew/oprimaryemulsionwasslowlyadded
to50mLoflightliquidparaﬃncontaining0.5%span-80,1%
ethylcellulose (50mg), 1%w/v magnesium stearate (50mg)
as a tensioactive agent, saturation, and droplet stabilizer
in the processing medium, respectively, under stirring in
diﬀerent rpm to form w/o/o multiple emulsion.The whole
system was stirred for about 3h. After stirring process was
over, the light liquid paraﬃnw a sd e c a n t e do ﬀ and micro-
spheres formed were collected by ﬁltration using ordinary
ﬁ l t e rp a p e r( p o r es i z e2 5 µm) and treated with petroleum
ether (40–60◦C) for several times to completely remove the
oil.Microspheresthenairdriedatroomtemperaturefor12h
and collected for further studies. The drug-to-polymer ratio
and stirring speed were varied in batches F1 to F9.
2.3. Assay of Stavudine. Stavudine was estimated by ultravi-
olet visible (UV/Vis) spectrophotometric method (Hitachi,
U-1700, Japan). Aqueous solution of stavudine was prepared
in phosphate buﬀer (pH 6.8), and absorbance was measured
on UV/Vis spectrophotometer at 266nm. The method was
validated for linearity, accuracy, and precision. The method
obeysBeer’sLawintheconcentrationrangeof5to50µg/mL.
When a standard drug solution was analyzed repeatedly (n =
6), the mean error (accuracy) and relative standard deviation
(precision) were found to be 0.7% and 1.2%, respectively.
2.4. Drug Entrapment Eﬃciency. Microspheres (50mg) were
crushed in a glass mortar and pastle, and the powdered
microsphere were suspended in 50mL phosphate buﬀer (pH
6.8). The resulting mixture was shaken by the magnetic
stirrer for 24h. The solution was ﬁltered, and the ﬁltrate
was analyzed for the drug content. The drug entrapment
eﬃciency was calculated using the following formula:
Drug Entrapment Eﬃciency
=
Practical drug content
Theoritical drug content
× 100.
(1)
2.5. Particle Size Analysis. Particle size of the microspheres
was measured by laser light scattering technique (Mastersizer
2000, Malvern, UK). The sizes of the completely dried
microspheresofdiﬀerentformulationsweremeasuredbydry
sample technique using dry sample adapter. The completely
dried particles were placed on the sample tray with an
in-built vacuum, and compressed air system was used to
suspend the particles. The laser obscuration range was
maintainedbetween1%and2%.Thevolumemeandiameter
(Vd) was recorded. After measurement of particle size of
each sample, the dry sample adopter was cleaned thoroughly
to avoid cross contamination. Each batch was analyzed in
triplicate, but the average values were considered in data
analysis.
2.6. In Vitro Drug Release Study. In vitro drug release study
of microspheres were carried out using USP XXIV paddle
type apparatus (Campbell Electronic, Mumbai, India) at
37 ± 1◦C and at 100rpm using 900mL phosphate buﬀer
(pH 6.8). Microsphere equivalent to 50mg of stavudine were
usedforthetest.Atpredeterminedintervals,5mLofaliquots
were withdrawn and replaced by the same volume of fresh
media. Aliquots were ﬁltered through a 0.45µmm e m b r a n e
ﬁlter, diluted suitably, and analysed spectrophotometrically.
Percent of drug dissolve at diﬀerent time intervals was
calculated using Lambert-Beer’s equation (Y = 0.0463X −
0.006) describe above. The t80% was calculated using the
Weibull equation [24]. The samples were then ﬁltered
through membrane ﬁlter (0.45µm) and diluted suitably.
The amount of drug present in the solution was then
analyzed spectrophotometrically at 225nm using UV-Visible
spectrophotometer (Shimadzu, UV-1700, Japan).
2.7. Scanning Electron Microscopy (SEM) Study. The surface
topography of the prepared microspheres was examined by
scanning electron microscope (Hitachi, S-3600N, Japan).
The samples were ﬁxed on brass stub using double-sided
tape and then gold-coated in vacuum by a sputter coater.
The SEM pictures were then taken at an excitation voltage
of 20kV.
2.8.FactorialDesign. Astatistical model incorporating inter-
active and polynomial terms was used to evaluate the re-
sponses:
Y = b0 +b1X1 +b2X2 +b12X1 X2 +b11X2
1 +b22X2
2,( 2 )
where Y is the dependent variable, b0 is the arithmetic
mean response of the 9runs. The main eﬀects (X1 and
X2) represent the average result of changing one factor at
a time from its low to high value. The interaction termsISRN Pharmaceutics 3
Table 1: 32 full factorial design layout.
Batch code Variable levels in coded Form Particle size (µm)∗ Drug entrapment eﬃciency (%)∗ t80% (minutes)∗
X1 X2
F1 −1 −1 221 55 283
F2 −1 0 212 49 281
F3 −1 1 206 47 264
F4 0 −1 251 64 284
F5 0 0 245 59 287
F6 0 1 234 57 300
F7 1 −1 290 70 571
F8 1 0 277 67 547
F9 1 1 269 64 456
Translation of coded levels in actual units
Variables level Low (−1) Medium (0) High (+1)
Drug-to-polymer ratio (X1) 1:1 1:2 1:3
Stirring speed (X2)rpm 800 1000 1200
∗Average of three determination.
Table 2: Summary of results of regression analysis.
Coeﬃcient b0 b1 b2 b11 b22 b12 R2
Entrapment eﬃciency (%) 59.07 8.33 −3.50 0.50 −1.24 1.26 0.9970
Mean particle size (µm) 244.38 32.83 −8.83 −1.50 1.67 −0.33 0.9979
t80% release (min) 348.79 124.33 −19.67 −24.00 79.72 −42.28 0.9694
(X1X2) show how the response changes when 2 factors are
simultaneously changed. The polynomial terms (X2
1 and X2
2)
are included to investigate nonlinearity.
3. Results andDiscussion
Microspheres of stavudine were prepared by emulsion sol-
vent diﬀusion technique using EC as a polymer due to its
hydrophobicity and release-controlling properties. At ﬁrst in
trial batch, viscosity of the polymer solution is optimized
since it is an important factor related to microspheres as
reported by Lee et al. [28]. Polymer concentration of 0.5%,
1%, and 2% w/v were selected for preliminary trials. Flake
formation was observed when ethylcellulose concentration
was used at a level of 0.5%, whereas maximum sphericity
was observed at the 1% level. The ethylcellulose solution was
found to be too viscous to pass through the syringe when
used at the 2% level. Therefore, 1% was found to be the
optimum concentration for the entire factorial batch.
The volume of secondary oil phase is an important
factor as related to the formulation of microspheres. The
volume of light liquid paraﬃn to be considered for the
factorial batch was selected on the basis of in vitro release
study. Diﬀerent volume of light liquid paraﬃn (from 20
to 60mL) was used in trial batch. As the volume of light
liquid paraﬃn is increased from 20mL to 50mL, the in vitro
release of stavudine is signiﬁcantly (P<. 05) decreased. On
the other hand, insigniﬁcant (P>. 05) decrease of the in
vitrodrug release was observed when the light liquid paraﬃn
volume was increased from 50mL to 60mL. Concentration
of span-80 plays an important role in the formulation
of microspheres prepared by emulsion solvent diﬀusion
technique. Therefore, suitable concentration of span-80 for
factorial batch was selected by taking into account their
aggregation phenomenon. Span-80 in the concentration of
0.5% was found suitable to prevent aggregation of the
microspheres.
The SEM photograph (Figure 1) revealed that the
drug-loaded microspheres are spherical. Microspheres pre-
pared containing higher amount of the polymer (1:3
drug:polymer ratio) exhibited smoother surfaces than those
prepared taking a lower amount of the polymer (1:1 and
1:2). Irregular surfaces and larger sizes of the microspheres
were observed for those prepared with a lower amount of
the polymer. This has greatly aﬀected the morphological
characteristics of the microspheres. As the drug-to-polymer
ratio was increased, more spherical microspheres with
smooth surfaces were obtained as suggested earlier [29].
On the basis of the preliminary trials a 32 full factorial
design was employed to study the eﬀect of independent
variables (i.e., drug-to-polymer ratio [X1] and the stirring
speed [X2]) on dependent variables (mean particle size, drug
entrapment eﬃciency, and t80%). The results depicted in
Table 1 clearly indicate that all the dependent variables are
strongly dependent on the selected independent variables as
they show a wide variation among the 9 batches (B1 to B9).
The ﬁtted equations (full models) relating the response (i.e.,
mean particle size, drug entrapment eﬃciency, and t80%)t o
the transformed factor are shown in Table 2.T h ep o l y n o m i a l
equations can be used to draw conclusions after considering4 ISRN Pharmaceutics
Table 3: Analysis of variance (ANOVA) for all three responses(a).
Entrapment eﬃciency (%) (Y1) P a r t i c l es i z e( µm) (Y2) t80% release (min) (Y3)
Source F P value F P value F P value
Model 3.81 .0801 1.08 .4838 169.68 .0001
X1 1.60 .2617 0.11 .7556 326.82 .0001
X2 1.82 .2349 0.70 .4419 1.15 .3325
X1X2 0.21 .6682 3.33 .1277 13.97 .0135
X12 0.014 .9103 0.61 .4685 263.25 .0001
X22 1.21 .3209 0.53 .5011 0.77 .4199
X12X2 0.30 .6061 0.19 .6826 8.83 .0311
X1X22 2.51 .1738 0.90 .3857 3.18 .1348
(a)Signiﬁcant eﬀect (P value <. 5) of factors on individual responses are shown in bold; t80% release: time of 80 percent of drug release; X1: drug-to-polymer
ratio; X2: stirring speed.
SE 16-Aug-07 x60 500µm OILR&D WD15.2mm 20.0kV
(a)
SE 17-Aug-07 x60 500µm OILR&D WD14.4mm 20.0kV
(b)
Figure 1: SEM drug-loaded ethylcellulose microsphere (a) before dissolution and (b) after dissolution.
themagnitudeofcoeﬃcientandthemathematicalsignitcar-
ries (i.e., positive or negative). The high values or correlation
coeﬃcient (Table 2) for the dependent variables indicate a
good ﬁt.
Mathematical relationship generated using multiple lin-
ear regression analysis for the studied variables are expressed
as follows:
Mean particle size
= 244.38 + 32.83X1 − 8.83X2 −1.50X1X2
+1 .67X2
1 −0.33X2
2,
(3)
Entrapment eﬃciency
= 59.07 + 8.33X1 −3.50X2 +0 .50X1X2
−1.24X2
1 +1 .26X2
2,
(4)
t80% = 348.79 + 124.33X1 −19.67X2 −24.00X1X2
+7 9 .72X2
1 −42.28X2
2.
(5)
All the polynomial equations were found to be statisti-
cally signiﬁcant (P<0.01), as determined using ANOVA
(Table 3), as per the provision of Design Expert software.
Particle size distribution was found to be unimodal.
Particle size analysis of microspheres was found to be in the
range of 206–290µm( Table 1). The factorial equation for
particle size showed good correlation coeﬃcient (0.9979).
ResultsoftheequationindicatethattheeﬀectofX1 (drug-to-
polymer ratio) is more signiﬁcant than X2 (stirring speed).
Moreover, stirring speed had a negative eﬀect on the particle
size (i.e., as the stirring speed increased, the particle size
decreased). As the stirring speed was increased, the size of
microdroplet of the emulsion was decreased resulting in
the formation of smaller size microparticles. These ﬁndings
are similar to those reported previously (27,28). Figures
2(a) and 2(b) depict a linear trend of mean particle size
in an ascending order with an increase in each variable. It
also shows that drug-to-polymer ratio has a comparatively
greater inﬂuence on the response variables than stirring
speed.
The drug entrapment eﬃciency is important variable
for assessing the drug loading capacity of microspheres.
This parameter is dependent on the process of prepara-
tion, physicochemical properties of drug, and formulation
variables. The drug entrapment eﬃciency varied from 47%
to 70% and showed good correlation coeﬃcient (0.9970).
Result of equation indicates the eﬀect of X1 (drug-to-
polymer ratio) is more signiﬁcant than X2 (stirring speed).ISRN Pharmaceutics 5
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Figure 2: (a) Response surface plot showing the inﬂuence of drug-to-polymer ratio and stirring speed on mean particle size (µm) and (b)
corresponding contour plot showing the relationship between various levels of 2 independent variables.
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Figure 3: (a) Response surface plot showing the inﬂuence of drug-to-polymer ratio and stirring speed on entrapment eﬃciency (%) and
(b) corresponding contour plot showing the relationship between various levels of 2 independent variables.
Moreover, stirring speed had a negative eﬀect on drug
entrapment eﬃciency (i.e., the stirring speed increased, the
particle size decreased, and thus drug entrapment eﬃciency
decreased). As the ratio of drug-to-polymer increased,
encapsulation eﬃciency increased; this is due to the fact that
higher ratio of drug-to-polymer would produce large size
droplets with decreased surface area, such that diﬀusion of
drug from such microsphere will be slow, resulting in higher
encapsulation eﬃciency. Figures 3(a) and 3(b) also exhibit
that entrapment eﬃciency vary in a nonlinear manner, but
in ascending pattern with an increase in each variable. But
at higher level of stirring speed the contour lines tend to be
linear. However, the eﬀect of drug-to-polymer seems to be
more pronounced as compared to stirring speed.
The release proﬁles of formulations appear to be slow
release with negligible burst eﬀect. The formulations with6 ISRN Pharmaceutics
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Figure 4: (a) Response surface plot showing the inﬂuence of drug-to-polymer ratio and stirring speed on t80% (minutes) and (b)
corresponding contour plot showing the relationship between various levels of 2 independent variables.
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Figure 5: In vitro release proﬁle of stavudine from ethylcellulose
microspheres of batch F7.
lower levels of drug-to-polymer ratio exhibited higher initial
burst in drug release. This could be attributed to the
dissolution of drug present initially at the surface of the
microspheres. However, the formulations showed little burst
eﬀect at higher drug-to-polymer ratio, ratifying better
sustenance of drug released. The values of t80% enhanced
markedlyfrom264minutes,observedalowlevelsofdrug-to-
polymer ratio and stirring speed, to as high as 571 minutes,
observed at high level of drug-to-polymer ratio and stirring
speed. This ﬁnding indicated considerable release-retarding
potential of the polymers for stavudine. Batch F7 exhibited a
hight80% of517minutesandsinceitisapromisingcandidate
for achieving drug release up to 12hrs. The drug release
proﬁle of batch F7 is shown in Figure 5. The percentage
in vitro drug release is highly dependent on drug-to-
polymer ratio and stirring speed. Results depicted in Table 2
indicate that the eﬀect of drug-to-polymer ratio (X1)i s
more signiﬁcant than stirring speed (X2). The stirring speed
had a negative eﬀect on t80% because as the stirring speed
increased, the particle size of microspheres is increased,
resulting in decrease of drug release. On the other hand,
as the drug-to-polymer ratio is increased, the drug loading
was decreased, resulting in decrease of drug release from
microspheres. On the other way, increase in polymer matrix
into the microspheres leads to an increased diﬀusional
path length and thereby decreased the overall drug release
from microspheres. Furthermore, smaller microspheres are
formed at lower polymer concentration and have larger
surface area exposed to dissolution medium. Figures 4(a)
and 4(b) show that t80% vary in nonlinear fashion, but
in ascending pattern with an increase of each variable.
The contour plot (Figure 5(b)) shows that drug-to-polymer
ratio has a comparatively greater inﬂuence on the response
variable than stirring speed.
The optimum formulation was selected based on the
criteria of attaining complete and controlled release with
highest possible entrapment eﬃciency. Upon “trading oﬀ”
various response variables, the following maximizing criteria
were adopted: mean particle size <300µm, entrapment
eﬃciency >60%, and t80% > 540 minutes. Accordingly, for-
m u l a t i o nF 7w a sr a n k e da sb e s tb a t c h .I no r d e rt od e t e r m i n e
the mechanism of drug release from the formulation F7,
the data obtained in vitro release study were ﬁtted to the
Korsemeyer-Peppas model in order to determine the “n”
value, which describes the drug release mechanism. The “n”
valueofalltheformulationswasbetween0.5and1indicating
that the mechanism of drug release was non-Fickian type
diﬀusion.ISRN Pharmaceutics 7
4. Conclusion
Sustained drug release in the current study indicates that
the hydrophobic matrix microspheres of stavudine, prepared
using EC, can successfully be prepared by emulsion solvent
diﬀusion technique. The results of a 32 factorial design
revealed that the drug-to-polymer ratio and stirring speed
are imperative to acquire sustained release and entrapment
eﬃciency. The microspheres of best batch exhibited mean
particle size of 290µm and entrapment eﬃciency of 70%.
The t80% of 571 minutes indicates that the microspheres of
stavudine could sustain the release of the drug for more than
12h.
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